Listing 3 - Actual negotiations

Indication:

Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older

Indication:

As part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult patients with AML or MDS at increased risk for standard conditioning therapies (In combination with fludarabine)

Indication:

Age-Related Macular Degeneration

Indication:

Diabetic Macular Edema

Indication:

Deleterious or suspected deleterious BRCA mutated (germline and/or somatic) metastatic castration resistant prostate cancer (mCRPC) in adult patients who are asymptomatic/mildly symptomatic, and in whom chemotherapy is not clinically indicated. (in combination with prednisone or prednisolone)

Indication:

In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features

Indication:

Schizophrenia

Indication:

Metastatic Colorectal Cancer (mCRC) patients with left-sided primary tumours that express wild-type RAS (In combination with chemotherapy)

Indication:

Hereditary transthyretin-mediated amyloidosis

Indication:

Primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer in adult patients who are candidates for systemic therapy (in combination with carboplatin and paclitaxel)